# Author Correction: Casdatifan durable response linked to HIF-2α in kidney cancer

The authors of a kidney cancer study issued a correction to their paper on casdatifan, a drug targeting HIF-2α. The correction addresses the reported connection between durable clinical response and HIF-2α biology. This clarifies the original findings for researchers and clinicians following the treatment's development.

**Importance:** 2/5

## Sources

### Science
- [Nature](https://www.nature.com/articles/s41586-026-10958-x) — 2026-08-04